Key statistics
On Friday, Ultragenyx Pharmaceutical Inc (0LIF:LSE) closed at 58.26, -2.58% below its 52-week high of 59.80, set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 58.26 |
Low | 58.26 |
Bid | -- |
Offer | -- |
Previous close | 59.80 |
Average volume | 236.44 |
---|---|
Shares outstanding | 92.17m |
Free float | 88.79m |
P/E (TTM) | -- |
Market cap | 5.41bn USD |
EPS (TTM) | -7.29 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 16:04 BST.
More ▼
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)
- Ultragenyx to Participate in Investor Conferences in September
- Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
- Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
- Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
- Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
More ▼